Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tower Hall Funabori

Apr 17, 2017 9:00 AM - Apr 18, 2017 6:00 PM

4-1-1 Funabori, Edogawa-ku, Tokyo, 134-0091 Japan

11th DIA Asia New Drug Conference in Japan

[Session 4] Changes and Benefits ICH E17 will Bring about

Session Chair(s)

Yoshiaki  Uyama, PhD, RPh

Yoshiaki Uyama, PhD, RPh

Associate Executive Director

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

The ICH-E17 guideline “General principle on planning/designing Multi-Regional Clinical Trials” is currently under consideration. This guideline suggests pooling some regions at the design stage if subjects in those regions are thought to be similar enough with respect to intrinsic and/or extrinsic factors. East Asia is expected to be effectively utilized as a pooled region given the similarities among countries. This guideline will have important implications in sample size allocation or selecting the region where the clinical study is to be conducted. In this session, speakers from PMDA and industry will present the changes that implementing this guideline will bring about, including changes in drug development strategy and specific examples of wise use of this guideline.

Speaker(s)

Shuji  Kamada

Changes and Benefits ICH E17 Will Bring About - Regulatory Perspective -

Shuji Kamada

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Reviewer, Office of New Drug V

Osamu  Komiyama

Points to be Considered in Order to Implement E17 Guideline - Industry Perspective

Osamu Komiyama

Pfizer R&D Japan G.K., Japan

Senior Manager, Statistical Research & Data Science

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.